Gilead Sciences (GILD) EBT Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) EBT Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -801,907.00 |
| 10 | Insmed | 27.67 Bn | 26.51 Bn | 358.27 Mn | 29,565.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -16,571.00 |
| Mar 31, 2026 | 1,234.00 |
| Dec 31, 2025 | -241.00 |
| Sep 30, 2025 | 3,420.00 |
| Jun 30, 2025 | 478.00 |
| Mar 31, 2025 | 9,183.00 |
| Dec 31, 2024 | 539.00 |
| Sep 30, 2024 | -2,020.00 |
| Jun 30, 2024 | 546.00 |
| Mar 31, 2024 | -8,756.00 |
| Dec 31, 2023 | -425.00 |
| Sep 30, 2023 | -166.00 |
| Jun 30, 2023 | 5.00 |
| Mar 31, 2023 | 2,277.00 |
| Dec 31, 2022 | 1,701.00 |
| Sep 30, 2022 | -1,179.00 |
| Jun 30, 2022 | -522.00 |
| Mar 31, 2022 | -3,755.00 |
| Dec 31, 2021 | -1,397.00 |
| Sep 30, 2021 | 3,378.00 |